Natural Immunity in Monkeys: A Promising Breakthrough Against COVID-19
Written on
Chapter 1: Understanding Natural Immunity
To combat the widespread devastation of the COVID-19 pandemic, enhancing immunity to SARS-CoV-2 is crucial. Whether through natural immunity or the immunity gained from vaccinations, both approaches are essential to curbing the virus's rampant spread. Currently, the global focus is on researching and implementing effective countermeasures against the disease. However, a comprehensive understanding of the immunological mechanisms at play with SARS-CoV-2 is still emerging. Fortunately, recent studies published in the journal 'Science' utilizing a rhesus monkey model provide promising insights.
Recent research has demonstrated that natural immunity can shield non-human primates from subsequent exposure to SARS-CoV-2. The monkey model is particularly relevant as it closely resembles human physiology compared to rodent models like mice, thereby enhancing the significance of these findings.
Section 1.1: The Rhesus Monkey Model for SARS-CoV-2
Dr. Dan H. Barouch, a Professor of Medicine at Harvard Medical School and Director at the Center for Virology and Vaccine Research, along with his team, established a rhesus monkey model for studying SARS-CoV-2 infection. They observed that the viral RNA levels peaked on the second day post-infection and were completely eliminated by days 21 to 28. Additionally, the monkeys developed a robust response of neutralizing antibodies against the virus.
On day 35 following the initial infection, the researchers reintroduced the same viral dose to the animals. Remarkably, the monkeys exhibited only a minimal level of viral RNA after re-exposure, indicating a swift immune response and a quicker clearance of the infection compared to the first exposure. This suggests that the monkeys had developed a natural immunity that effectively protected them from re-infection, which is encouraging for future research.
Researchers say COVID-19 vaccine effective in monkey tests - YouTube
This video discusses how recent studies on monkeys show the effectiveness of COVID-19 vaccines, providing hope for broader human applications.
Section 1.2: The Potential for Vaccine Development
While there is currently insufficient evidence regarding whether humans gain protection from re-exposure after recovering from SARS-CoV-2, the insights gained from monkey studies may inform vaccine development, antibody-based therapies, and herd immunity modeling.
Additionally, another study revealed that DNA vaccines effectively protected rhesus monkeys from SARS-CoV-2. Among various vaccines tested, a DNA vaccine encoding the full-length spike protein demonstrated the highest level of protection. This finding also supports the ongoing clinical trials for the mRNA vaccine (mRNA 1273) developed by Moderna Therapeutics. Notably, this mRNA encodes a stabilized version of the spike protein, and phase 1 trials indicated that participants developed neutralizing antibody levels comparable to those seen in individuals who recovered from the virus, two weeks after their second vaccine dose.
Monkeys infected with COVID-19 develop immunity in studies | WION - YouTube
This video explores how monkeys infected with COVID-19 develop immunity, shedding light on vaccine efficacy and human immunity.
Chapter 2: Looking Ahead
Photo by Tama66 from Pixabay
In conclusion, there is hope for a brighter future in the fight against COVID-19. As Dr. Barouch stated, "our findings increase optimism that the development of COVID-19 vaccines will be possible." Ongoing research will deepen our understanding of the duration of protection provided by natural immunity and the most effective vaccine strategies against SARS-CoV-2.